Immunicum AB (“Immunicum” publ; IMMU.ST), a biopharmaceutical company focused on therapies addressing tumor recurrence and hard-to-treat established tumors, today announced that its Annual Report for 2021 is now available on the Company’s corporate website: www.immunicum.com. Immunicum shareholders can request a printed copy of the 2021 Annual Report by contacting the company by e-mail, ir@immunicum.com. This information is information that Immunicum is obliged to make public pursuant to the Securities Markets Act. The information was submitted for publication, through the agency of the contact person set out below, at 8:00 am CEST on 15 April 2022. FOR MORE INFORMATION, PLEASE CONTACT: Erik Manting Chief Executive Officer E-mail: ir@immunicum.com INVESTOR RELATIONS Brendan Payne Stern Investor Relations Telephone: +1 212-698-8695 E-mail: brendan.payne@sternir.com MEDIA RELATIONS Mario Brkulj Valency Communications Telephone: +49 160 9352 9951 E-mail: mbrkulj@valencycomms.eu ABOUT IMMUNICUM AB (PUBL)Immunicum is a biopharmaceutical company focused on therapies addressing tumor recurrence and hard-to-treat established tumors, two key challenges in oncology. We are leveraging our unparalleled expertise in allogeneic dendritic cell biology to develop an advanced clinical pipeline of novel, off-the-shelf, cell-based therapies for blood-borne and solid tumors. Based in Sweden and the Netherlands, Immunicum is publicly traded on the Nasdaq Stockholm. www.immunicum.com
Attachments
220415_Immunicum_AR2021_ENG
Immunicum_AnnualReport_2021
Immunicum_Årsredovisning_ESEF_2021